Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.

Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device. Clin Appl Thromb Hemost. 2014 Apr;20(3):338-40 Authors: Soliman AA, Csorba R, Ullrich A, Tsikouras P, Rath W, von Tempelhoff GF PMID: 24577843 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/24577843?dopt=Abstract

Source: Clinical Breast Cancer - March 3, 2014 Category: Cancer & Oncology Authors: Soliman AA, Csorba R, Ullrich A, Tsikouras P, Rath W, von Tempelhoff GF Tags: Clin Appl Thromb Hemost Source Type: research

More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy